Alimera Sciences (ALIM) Misses Q1 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Alimera Sciences Announces First Quarter 2016 Financial Results
May 4, 2016 4:23 PM EDTFirst quarter revenue improved 49% compared to first quarter 2015 due to increasing ILUVIEN® sales in the U.S.Record benefit investigations in the first quarter indicate increasing physician demandOver 5,000 eyes treated with ILUVIEN® in four primary marketsAlimera to host conference call on May 5, 2016 at 10:00 AM ET
ATLANTA, May 04, 2016 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of... More
